The CameL study [11] was the first Phase III clinical study conducted on the Chinese population, enrolling patients with Stage IIIB or IV EGFR/ALK wild‐type nonsquamous NSCLC who had not received systemic treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.